These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 20837954)

  • 1. Phase 0 clinical trials in oncology: an exploratory methodology for constructing a study with patients undergoing surgery for metastatic disease.
    Pocard M; Soria JC; Aldaz-Carroll L; Bellet D
    J Clin Oncol; 2010 Oct; 28(30):4551-3. PubMed ID: 20837954
    [No Abstract]   [Full Text] [Related]  

  • 2. Systematic survey of therapeutic trials for metastatic colorectal cancer: room for improvement in the critical pathway.
    Kopetz S; Overman M; Chang DZ; Glover KY; Shureiqi I; Wolff RA; Abbruzzese JL; Eng C
    J Clin Oncol; 2008 Apr; 26(12):2000-5. PubMed ID: 18421052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase 0 clinical trials in oncology: a paradigm shift for early drug development?
    Takimoto CH
    Cancer Chemother Pharmacol; 2009 Mar; 63(4):703-9. PubMed ID: 18615251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lessons learned from independent central review.
    Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
    Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erythropoietin in cancer-related anemia.
    Fenner MH; Ganser A
    Curr Opin Oncol; 2008 Nov; 20(6):685-9. PubMed ID: 18841051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The ODAC chronicles--part 2. Statistics and clinical medicine in the USA: the triumph of science over art?
    Grillo-López AJ
    Expert Rev Anticancer Ther; 2004 Dec; 4(6):941-4. PubMed ID: 15606323
    [No Abstract]   [Full Text] [Related]  

  • 7. Controversy trails adaptive clinical trials.
    Goozner M
    J Natl Cancer Inst; 2012 Sep; 104(18):1347-8. PubMed ID: 22984199
    [No Abstract]   [Full Text] [Related]  

  • 8. Should the FDA be the doctor of last resort?
    DeVita VT
    Nat Clin Pract Oncol; 2005 Sep; 2(9):423. PubMed ID: 16264991
    [No Abstract]   [Full Text] [Related]  

  • 9. Trend toward noninferiority trials may mean more difficult interpretation of trial results.
    Tuma RS
    J Natl Cancer Inst; 2007 Dec; 99(23):1746-8. PubMed ID: 18042926
    [No Abstract]   [Full Text] [Related]  

  • 10. Sharks do get cancer: few surprises in cartilage research.
    Finkelstein JB
    J Natl Cancer Inst; 2005 Nov; 97(21):1562-3. PubMed ID: 16264172
    [No Abstract]   [Full Text] [Related]  

  • 11. Progression-free survival: gaining on overall survival as a gold standard and accelerating drug development.
    Lebwohl D; Kay A; Berg W; Baladi JF; Zheng J
    Cancer J; 2009; 15(5):386-94. PubMed ID: 19826358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical trial design in metastatic breast cancer: a commentary.
    Levine M
    Can J Oncol; 1995 Dec; 5 Suppl 1():40-2. PubMed ID: 8853523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase 0 clinical trials in cancer drug development: from FDA guidance to clinical practice.
    Kinders R; Parchment RE; Ji J; Kummar S; Murgo AJ; Gutierrez M; Collins J; Rubinstein L; Pickeral O; Steinberg SM; Yang S; Hollingshead M; Chen A; Helman L; Wiltrout R; Simpson M; Tomaszewski JE; Doroshow JH
    Mol Interv; 2007 Dec; 7(6):325-34. PubMed ID: 18199854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase 0 clinical trials will overcome stagnation of anticancer drug development?
    Mendoza L
    Klin Onkol; 2011; 24(2):143-5. PubMed ID: 21638998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trials and tribulations.
    Nat Rev Drug Discov; 2007 May; 6(5):331. PubMed ID: 17539051
    [No Abstract]   [Full Text] [Related]  

  • 16. Adaptive design may hasten clinical trials.
    Schmidt C
    J Natl Cancer Inst; 2007 Jan; 99(2):108-9. PubMed ID: 17227993
    [No Abstract]   [Full Text] [Related]  

  • 17. Can single-patient investigational new drug studies hurry slow trains to the fast track?
    Chenoweth D
    Drug Discov Today; 2006 Mar; 11(5-6):185-6. PubMed ID: 16580594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and endpoints of clinical trials in hepatocellular carcinoma.
    Llovet JM; Di Bisceglie AM; Bruix J; Kramer BS; Lencioni R; Zhu AX; Sherman M; Schwartz M; Lotze M; Talwalkar J; Gores GJ;
    J Natl Cancer Inst; 2008 May; 100(10):698-711. PubMed ID: 18477802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Food and Drug Administration requirements for approval of new anticancer drugs.
    Johnson JR; Temple R
    Cancer Treat Rep; 1985 Oct; 69(10):1155-9. PubMed ID: 4042094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of toxicity in cooperative oncology clinical trials: the long and short of it.
    Gwede CK; Johnson DJ; Daniels SS; Trotti A
    J Oncol Manag; 2002; 11(2):15-21. PubMed ID: 11989815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.